Checklist For Identifying Cancer Patients In Secondary Data

Published May 17, 2013
Bolton, MA, USA - The use of secondary data sources is growing in oncology health services research. Identifying patients with cancer from these data can be difficult due to the lack of clinical detail in secondary data. As a result, researchers develop algorithms or groups of codes to identify specific groups of cancer patients in secondary data. Therefore, researchers must critically evaluate whether published algorithms are suitable for their studies or develop and defend their own algorithm. The ISPOR Oncology Good Outcomes Research Practices Working Group reviewed articles using secondary data to study cancer populations. Findings from the review were used to develop a checklist for identifying potential methodological and reporting issues using secondary data. This checklist will assist decision makers and reviewers to evaluate the quality of studies using secondary data and provide guidance for researchers working with secondary data. Kathy L. Schulman, MA, Principal at Outcomes Research Solutions and first author of the study comments, “Secondary data are critical in oncology health services research. We hope this checklist will facilitate the standardization of reporting and reviewing of future publications.” The full study, “A Checklist for Ascertaining Study Cohorts in Oncology Health Services Research Using Secondary Data: Report of the ISPOR Oncology Good Outcomes Research Practices Working Group,” is published in Value in Health.

Value in Health (ISSN 1098-3015) publishes papers, concepts, and ideas that advance the field of pharmacoeconomics and outcomes research as well as policy papers to help health care leaders make evidence-based decisions. The journal is published bi-monthly and has over 8,000 subscribers (clinicians, decision makers, and researchers worldwide).

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is a nonprofit, international, educational and scientific organization that strives to increase the efficiency, effectiveness, and fairness of health care resource use to improve health.

For more information: www.ispor.org

Related Stories

The Ozempic Paradox: How Spending Billions on Weight-Loss Drug Would Actually Reduce Overall Medicare Costs

Oct 14, 2025

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a landmark study by researchers at the University of Washington, Curta, Inc, and the University of North Carolina showing that broad Medicare coverage of semaglutide in diabetes, obesity, and liver disease could generate significant cost savings while delivering substantial health benefits to beneficiaries. The report, “Comprehensive Access to Semaglutide: Clinical and Economic Implications for Medicare,” was published in the October 2025 issue of Value in Health.

ISPOR Launches New Content on Whole Health

Sep 23, 2025

ISPOR announced that it has launched new website content on whole health, a topic of increasing importance as health systems across the globe grapple with providing the best possible healthcare to patients within constrained budgets.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×